nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—ABCG2—Sulfasalazine—Crohn's disease	0.0442	0.55	CbGbCtD
Regorafenib—RET—enteric nervous system—Crohn's disease	0.0414	0.145	CbGeAlD
Regorafenib—KIT—myenteric nerve plexus—Crohn's disease	0.0207	0.0725	CbGeAlD
Regorafenib—CYP2C19—Prednisone—Crohn's disease	0.0158	0.197	CbGbCtD
Regorafenib—PDGFRA—penis—Crohn's disease	0.0147	0.0514	CbGeAlD
Regorafenib—ABCB1—Prednisone—Crohn's disease	0.0128	0.159	CbGbCtD
Regorafenib—Lipase increased—Mesalazine—Crohn's disease	0.00854	0.0386	CcSEcCtD
Regorafenib—CYP3A4—Prednisone—Crohn's disease	0.00764	0.095	CbGbCtD
Regorafenib—Polyp—Mercaptopurine—Crohn's disease	0.0076	0.0343	CcSEcCtD
Regorafenib—Cyst—Mercaptopurine—Crohn's disease	0.00692	0.0312	CcSEcCtD
Regorafenib—Hepatotoxicity—Mercaptopurine—Crohn's disease	0.00599	0.027	CcSEcCtD
Regorafenib—DDR2—smooth muscle tissue—Crohn's disease	0.00559	0.0196	CbGeAlD
Regorafenib—DDR2—skin of body—Crohn's disease	0.00552	0.0193	CbGeAlD
Regorafenib—Liver injury—Mercaptopurine—Crohn's disease	0.0055	0.0248	CcSEcCtD
Regorafenib—Amylase increased—Mesalazine—Crohn's disease	0.00527	0.0238	CcSEcCtD
Regorafenib—FGFR2—mouth—Crohn's disease	0.0051	0.0179	CbGeAlD
Regorafenib—DDR2—mammalian vulva—Crohn's disease	0.00503	0.0176	CbGeAlD
Regorafenib—Hyperuricaemia—Mercaptopurine—Crohn's disease	0.00499	0.0225	CcSEcCtD
Regorafenib—FRK—lymphoid tissue—Crohn's disease	0.00498	0.0175	CbGeAlD
Regorafenib—PDGFRA—gall bladder—Crohn's disease	0.00498	0.0174	CbGeAlD
Regorafenib—Blood uric acid increased—Mercaptopurine—Crohn's disease	0.00471	0.0213	CcSEcCtD
Regorafenib—Polyp—Azathioprine—Crohn's disease	0.00453	0.0204	CcSEcCtD
Regorafenib—DDR2—lymphoid tissue—Crohn's disease	0.00447	0.0157	CbGeAlD
Regorafenib—DDR2—digestive system—Crohn's disease	0.00441	0.0155	CbGeAlD
Regorafenib—Neoplasm—Mercaptopurine—Crohn's disease	0.00418	0.0189	CcSEcCtD
Regorafenib—Cyst—Azathioprine—Crohn's disease	0.00412	0.0186	CcSEcCtD
Regorafenib—KIT—gall bladder—Crohn's disease	0.00398	0.0139	CbGeAlD
Regorafenib—Hypomagnesaemia—Mesalazine—Crohn's disease	0.00395	0.0178	CcSEcCtD
Regorafenib—PDGFRB—gall bladder—Crohn's disease	0.00389	0.0136	CbGeAlD
Regorafenib—Nail disorder—Mesalazine—Crohn's disease	0.00387	0.0175	CcSEcCtD
Regorafenib—Hepatotoxicity—Azathioprine—Crohn's disease	0.00357	0.0161	CcSEcCtD
Regorafenib—KIT—mouth—Crohn's disease	0.00354	0.0124	CbGeAlD
Regorafenib—FLT4—epithelium—Crohn's disease	0.00353	0.0124	CbGeAlD
Regorafenib—EPHX2—mammalian vulva—Crohn's disease	0.0034	0.0119	CbGeAlD
Regorafenib—Liver injury—Azathioprine—Crohn's disease	0.00327	0.0148	CcSEcCtD
Regorafenib—Hepatotoxicity—Mesalazine—Crohn's disease	0.00325	0.0147	CcSEcCtD
Regorafenib—RET—epithelium—Crohn's disease	0.00312	0.0109	CbGeAlD
Regorafenib—FGFR1—mammalian vulva—Crohn's disease	0.00302	0.0106	CbGeAlD
Regorafenib—Liver injury—Mesalazine—Crohn's disease	0.00298	0.0135	CcSEcCtD
Regorafenib—FGFR2—epithelium—Crohn's disease	0.00296	0.0104	CbGeAlD
Regorafenib—EPHA2—epithelium—Crohn's disease	0.00291	0.0102	CbGeAlD
Regorafenib—Proteinuria—Mesalazine—Crohn's disease	0.00286	0.0129	CcSEcCtD
Regorafenib—FGFR2—smooth muscle tissue—Crohn's disease	0.00286	0.01	CbGeAlD
Regorafenib—TEK—epithelium—Crohn's disease	0.00284	0.00996	CbGeAlD
Regorafenib—FGFR2—skin of body—Crohn's disease	0.00282	0.00988	CbGeAlD
Regorafenib—Protein urine present—Mesalazine—Crohn's disease	0.00282	0.0127	CcSEcCtD
Regorafenib—Musculoskeletal stiffness—Mesalazine—Crohn's disease	0.0028	0.0126	CcSEcCtD
Regorafenib—FLT1—epithelium—Crohn's disease	0.00275	0.00963	CbGeAlD
Regorafenib—Hypocalcaemia—Mesalazine—Crohn's disease	0.00274	0.0124	CcSEcCtD
Regorafenib—TEK—smooth muscle tissue—Crohn's disease	0.00274	0.0096	CbGeAlD
Regorafenib—RAF1—epithelium—Crohn's disease	0.00273	0.00957	CbGeAlD
Regorafenib—UGT1A9—digestive system—Crohn's disease	0.00273	0.00955	CbGeAlD
Regorafenib—FLT4—lymphoid tissue—Crohn's disease	0.00272	0.00954	CbGeAlD
Regorafenib—FLT1—smooth muscle tissue—Crohn's disease	0.00265	0.00928	CbGeAlD
Regorafenib—RAF1—smooth muscle tissue—Crohn's disease	0.00263	0.00922	CbGeAlD
Regorafenib—RAF1—skin of body—Crohn's disease	0.0026	0.0091	CbGeAlD
Regorafenib—Lymphopenia—Prednisone—Crohn's disease	0.00259	0.0117	CcSEcCtD
Regorafenib—EPHA2—mammalian vulva—Crohn's disease	0.00253	0.00885	CbGeAlD
Regorafenib—Stomatitis—Mercaptopurine—Crohn's disease	0.00252	0.0114	CcSEcCtD
Regorafenib—DDR2—lymph node—Crohn's disease	0.00252	0.00883	CbGeAlD
Regorafenib—Neoplasm—Azathioprine—Crohn's disease	0.00249	0.0112	CcSEcCtD
Regorafenib—PDGFRA—smooth muscle tissue—Crohn's disease	0.00248	0.00869	CbGeAlD
Regorafenib—Hepatobiliary disease—Mercaptopurine—Crohn's disease	0.00245	0.011	CcSEcCtD
Regorafenib—RET—lymphoid tissue—Crohn's disease	0.0024	0.00842	CbGeAlD
Regorafenib—MAPK11—lymph node—Crohn's disease	0.00239	0.00837	CbGeAlD
Regorafenib—FLT1—mammalian vulva—Crohn's disease	0.00238	0.00835	CbGeAlD
Regorafenib—RET—digestive system—Crohn's disease	0.00237	0.00832	CbGeAlD
Regorafenib—RAF1—mammalian vulva—Crohn's disease	0.00237	0.0083	CbGeAlD
Regorafenib—KDR—epithelium—Crohn's disease	0.00232	0.00814	CbGeAlD
Regorafenib—FGFR2—digestive system—Crohn's disease	0.00226	0.0079	CbGeAlD
Regorafenib—EPHA2—lymphoid tissue—Crohn's disease	0.00224	0.00786	CbGeAlD
Regorafenib—KDR—smooth muscle tissue—Crohn's disease	0.00224	0.00784	CbGeAlD
Regorafenib—EPHA2—digestive system—Crohn's disease	0.00222	0.00777	CbGeAlD
Regorafenib—TEK—lymphoid tissue—Crohn's disease	0.00219	0.00767	CbGeAlD
Regorafenib—FLT1—lymphoid tissue—Crohn's disease	0.00212	0.00742	CbGeAlD
Regorafenib—RAF1—lymphoid tissue—Crohn's disease	0.0021	0.00737	CbGeAlD
Regorafenib—FLT1—digestive system—Crohn's disease	0.00209	0.00733	CbGeAlD
Regorafenib—RAF1—digestive system—Crohn's disease	0.00208	0.00728	CbGeAlD
Regorafenib—Hypothyroidism—Prednisone—Crohn's disease	0.00207	0.00934	CcSEcCtD
Regorafenib—KIT—epithelium—Crohn's disease	0.00206	0.00721	CbGeAlD
Regorafenib—Gastroenteritis—Mesalazine—Crohn's disease	0.00206	0.00928	CcSEcCtD
Regorafenib—Alopecia—Mercaptopurine—Crohn's disease	0.00205	0.00926	CcSEcCtD
Regorafenib—Malnutrition—Mercaptopurine—Crohn's disease	0.00202	0.00913	CcSEcCtD
Regorafenib—KDR—mammalian vulva—Crohn's disease	0.00201	0.00706	CbGeAlD
Regorafenib—PDGFRB—epithelium—Crohn's disease	0.00201	0.00704	CbGeAlD
Regorafenib—KIT—smooth muscle tissue—Crohn's disease	0.00198	0.00695	CbGeAlD
Regorafenib—PDGFRA—lymphoid tissue—Crohn's disease	0.00198	0.00695	CbGeAlD
Regorafenib—PDGFRA—digestive system—Crohn's disease	0.00196	0.00686	CbGeAlD
Regorafenib—KIT—skin of body—Crohn's disease	0.00196	0.00686	CbGeAlD
Regorafenib—PDGFRB—smooth muscle tissue—Crohn's disease	0.00194	0.00679	CbGeAlD
Regorafenib—PDGFRB—skin of body—Crohn's disease	0.00191	0.0067	CbGeAlD
Regorafenib—UGT1A1—digestive system—Crohn's disease	0.00187	0.00655	CbGeAlD
Regorafenib—Anaemia—Mercaptopurine—Crohn's disease	0.00187	0.00844	CcSEcCtD
Regorafenib—Leukopenia—Mercaptopurine—Crohn's disease	0.00181	0.00817	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Azathioprine—Crohn's disease	0.0018	0.00813	CcSEcCtD
Regorafenib—KDR—lymphoid tissue—Crohn's disease	0.00179	0.00627	CbGeAlD
Regorafenib—KIT—mammalian vulva—Crohn's disease	0.00179	0.00626	CbGeAlD
Regorafenib—BRAF—lymph node—Crohn's disease	0.00178	0.00624	CbGeAlD
Regorafenib—KDR—digestive system—Crohn's disease	0.00177	0.00619	CbGeAlD
Regorafenib—PDGFRB—mammalian vulva—Crohn's disease	0.00174	0.00611	CbGeAlD
Regorafenib—ABL1—smooth muscle tissue—Crohn's disease	0.00173	0.00605	CbGeAlD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—Crohn's disease	0.00171	0.00772	CcSEcCtD
Regorafenib—ABL1—skin of body—Crohn's disease	0.0017	0.00597	CbGeAlD
Regorafenib—EPHX2—lymph node—Crohn's disease	0.0017	0.00597	CbGeAlD
Regorafenib—Dry skin—Mesalazine—Crohn's disease	0.00167	0.00754	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Mesalazine—Crohn's disease	0.00164	0.00741	CcSEcCtD
Regorafenib—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.00162	0.00729	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Mesalazine—Crohn's disease	0.00161	0.00725	CcSEcCtD
Regorafenib—Skin disorder—Mercaptopurine—Crohn's disease	0.0016	0.00724	CcSEcCtD
Regorafenib—Endocrine disorder—Prednisone—Crohn's disease	0.0016	0.00723	CcSEcCtD
Regorafenib—KIT—lymphoid tissue—Crohn's disease	0.00159	0.00556	CbGeAlD
Regorafenib—KIT—digestive system—Crohn's disease	0.00157	0.00549	CbGeAlD
Regorafenib—ABL1—mammalian vulva—Crohn's disease	0.00155	0.00545	CbGeAlD
Regorafenib—PDGFRB—lymphoid tissue—Crohn's disease	0.00155	0.00543	CbGeAlD
Regorafenib—Infestation—Azathioprine—Crohn's disease	0.00154	0.00696	CcSEcCtD
Regorafenib—Infestation NOS—Azathioprine—Crohn's disease	0.00154	0.00696	CcSEcCtD
Regorafenib—FLT4—lymph node—Crohn's disease	0.00154	0.00538	CbGeAlD
Regorafenib—PDGFRB—digestive system—Crohn's disease	0.00153	0.00536	CbGeAlD
Regorafenib—Stevens-Johnson syndrome—Azathioprine—Crohn's disease	0.00153	0.0069	CcSEcCtD
Regorafenib—FGFR1—lymph node—Crohn's disease	0.00151	0.00531	CbGeAlD
Regorafenib—Neutropenia—Mesalazine—Crohn's disease	0.00147	0.00665	CcSEcCtD
Regorafenib—Hepatobiliary disease—Azathioprine—Crohn's disease	0.00146	0.00658	CcSEcCtD
Regorafenib—Decreased appetite—Mercaptopurine—Crohn's disease	0.00143	0.00648	CcSEcCtD
Regorafenib—Weight decreased—Mesalazine—Crohn's disease	0.00142	0.00643	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.00142	0.00643	CcSEcCtD
Regorafenib—Infestation—Mesalazine—Crohn's disease	0.0014	0.00634	CcSEcCtD
Regorafenib—Infestation NOS—Mesalazine—Crohn's disease	0.0014	0.00634	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Mesalazine—Crohn's disease	0.00139	0.00628	CcSEcCtD
Regorafenib—Haemoglobin—Azathioprine—Crohn's disease	0.00139	0.00628	CcSEcCtD
Regorafenib—Haemorrhage—Azathioprine—Crohn's disease	0.00138	0.00625	CcSEcCtD
Regorafenib—ABL1—lymphoid tissue—Crohn's disease	0.00138	0.00484	CbGeAlD
Regorafenib—Stomatitis—Mesalazine—Crohn's disease	0.00137	0.00618	CcSEcCtD
Regorafenib—ABL1—digestive system—Crohn's disease	0.00136	0.00478	CbGeAlD
Regorafenib—RET—lymph node—Crohn's disease	0.00136	0.00475	CbGeAlD
Regorafenib—Hepatobiliary disease—Mesalazine—Crohn's disease	0.00133	0.00599	CcSEcCtD
Regorafenib—Erythema multiforme—Azathioprine—Crohn's disease	0.00131	0.00591	CcSEcCtD
Regorafenib—Body temperature increased—Mercaptopurine—Crohn's disease	0.0013	0.00589	CcSEcCtD
Regorafenib—Haemoglobin—Mesalazine—Crohn's disease	0.00127	0.00572	CcSEcCtD
Regorafenib—EPHA2—lymph node—Crohn's disease	0.00127	0.00444	CbGeAlD
Regorafenib—Haemorrhage—Mesalazine—Crohn's disease	0.00126	0.00569	CcSEcCtD
Regorafenib—Mediastinal disorder—Azathioprine—Crohn's disease	0.00125	0.00563	CcSEcCtD
Regorafenib—Urinary tract disorder—Mesalazine—Crohn's disease	0.00124	0.00562	CcSEcCtD
Regorafenib—Connective tissue disorder—Mesalazine—Crohn's disease	0.00124	0.00559	CcSEcCtD
Regorafenib—Urethral disorder—Mesalazine—Crohn's disease	0.00124	0.00558	CcSEcCtD
Regorafenib—TEK—lymph node—Crohn's disease	0.00123	0.00433	CbGeAlD
Regorafenib—Alopecia—Azathioprine—Crohn's disease	0.00122	0.00552	CcSEcCtD
Regorafenib—FLT1—lymph node—Crohn's disease	0.00119	0.00418	CbGeAlD
Regorafenib—Erythema multiforme—Mesalazine—Crohn's disease	0.00119	0.00538	CcSEcCtD
Regorafenib—RAF1—lymph node—Crohn's disease	0.00119	0.00416	CbGeAlD
Regorafenib—Cardiac disorder—Mesalazine—Crohn's disease	0.00117	0.00528	CcSEcCtD
Regorafenib—Angiopathy—Mesalazine—Crohn's disease	0.00114	0.00516	CcSEcCtD
Regorafenib—Mediastinal disorder—Mesalazine—Crohn's disease	0.00114	0.00513	CcSEcCtD
Regorafenib—Diarrhoea—Mercaptopurine—Crohn's disease	0.00113	0.0051	CcSEcCtD
Regorafenib—PDGFRA—lymph node—Crohn's disease	0.00112	0.00392	CbGeAlD
Regorafenib—Alopecia—Mesalazine—Crohn's disease	0.00111	0.00503	CcSEcCtD
Regorafenib—Anaemia—Azathioprine—Crohn's disease	0.00111	0.00503	CcSEcCtD
Regorafenib—Leukopenia—Azathioprine—Crohn's disease	0.00108	0.00487	CcSEcCtD
Regorafenib—Vomiting—Mercaptopurine—Crohn's disease	0.00105	0.00474	CcSEcCtD
Regorafenib—Rash—Mercaptopurine—Crohn's disease	0.00104	0.0047	CcSEcCtD
Regorafenib—Dermatitis—Mercaptopurine—Crohn's disease	0.00104	0.00469	CcSEcCtD
Regorafenib—Tremor—Mesalazine—Crohn's disease	0.00103	0.00464	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.00102	0.0046	CcSEcCtD
Regorafenib—Anaemia—Mesalazine—Crohn's disease	0.00101	0.00458	CcSEcCtD
Regorafenib—CYP2C19—digestive system—Crohn's disease	0.00101	0.00355	CbGeAlD
Regorafenib—KDR—lymph node—Crohn's disease	0.00101	0.00354	CbGeAlD
Regorafenib—CYP2B6—skin of body—Crohn's disease	0.000991	0.00347	CbGeAlD
Regorafenib—Leukopenia—Mesalazine—Crohn's disease	0.000982	0.00443	CcSEcCtD
Regorafenib—ABCG2—mammalian vulva—Crohn's disease	0.00098	0.00343	CbGeAlD
Regorafenib—Nausea—Mercaptopurine—Crohn's disease	0.00098	0.00442	CcSEcCtD
Regorafenib—Infection—Azathioprine—Crohn's disease	0.000977	0.00441	CcSEcCtD
Regorafenib—Thrombocytopenia—Azathioprine—Crohn's disease	0.000963	0.00435	CcSEcCtD
Regorafenib—Skin disorder—Azathioprine—Crohn's disease	0.000955	0.00431	CcSEcCtD
Regorafenib—Hypertension—Mesalazine—Crohn's disease	0.000947	0.00428	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.000928	0.00419	CcSEcCtD
Regorafenib—Dry mouth—Mesalazine—Crohn's disease	0.000914	0.00412	CcSEcCtD
Regorafenib—KIT—lymph node—Crohn's disease	0.000894	0.00313	CbGeAlD
Regorafenib—Infection—Mesalazine—Crohn's disease	0.00089	0.00402	CcSEcCtD
Regorafenib—Dry skin—Prednisone—Crohn's disease	0.000884	0.00399	CcSEcCtD
Regorafenib—Nervous system disorder—Mesalazine—Crohn's disease	0.000878	0.00396	CcSEcCtD
Regorafenib—Hypokalaemia—Prednisone—Crohn's disease	0.000877	0.00396	CcSEcCtD
Regorafenib—Thrombocytopenia—Mesalazine—Crohn's disease	0.000877	0.00396	CcSEcCtD
Regorafenib—PDGFRB—lymph node—Crohn's disease	0.000874	0.00306	CbGeAlD
Regorafenib—Skin disorder—Mesalazine—Crohn's disease	0.00087	0.00393	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Prednisone—Crohn's disease	0.00085	0.00384	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.000849	0.00383	CcSEcCtD
Regorafenib—Gastrointestinal pain—Azathioprine—Crohn's disease	0.000804	0.00363	CcSEcCtD
Regorafenib—CYP2B6—lymphoid tissue—Crohn's disease	0.000803	0.00281	CbGeAlD
Regorafenib—CYP2B6—digestive system—Crohn's disease	0.000793	0.00278	CbGeAlD
Regorafenib—CYP2C9—digestive system—Crohn's disease	0.000785	0.00275	CbGeAlD
Regorafenib—Neutropenia—Prednisone—Crohn's disease	0.000779	0.00352	CcSEcCtD
Regorafenib—ABL1—lymph node—Crohn's disease	0.000779	0.00273	CbGeAlD
Regorafenib—Decreased appetite—Mesalazine—Crohn's disease	0.000778	0.00351	CcSEcCtD
Regorafenib—Body temperature increased—Azathioprine—Crohn's disease	0.000777	0.00351	CcSEcCtD
Regorafenib—Abdominal pain—Azathioprine—Crohn's disease	0.000777	0.00351	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.000773	0.00349	CcSEcCtD
Regorafenib—Fatigue—Mesalazine—Crohn's disease	0.000772	0.00349	CcSEcCtD
Regorafenib—Pain—Mesalazine—Crohn's disease	0.000766	0.00346	CcSEcCtD
Regorafenib—Weight decreased—Prednisone—Crohn's disease	0.000754	0.0034	CcSEcCtD
Regorafenib—Acute coronary syndrome—Prednisone—Crohn's disease	0.000732	0.00331	CcSEcCtD
Regorafenib—Gastrointestinal pain—Mesalazine—Crohn's disease	0.000732	0.00331	CcSEcCtD
Regorafenib—Myocardial infarction—Prednisone—Crohn's disease	0.000728	0.00329	CcSEcCtD
Regorafenib—Abdominal pain—Mesalazine—Crohn's disease	0.000708	0.0032	CcSEcCtD
Regorafenib—Body temperature increased—Mesalazine—Crohn's disease	0.000708	0.0032	CcSEcCtD
Regorafenib—Diarrhoea—Azathioprine—Crohn's disease	0.000673	0.00304	CcSEcCtD
Regorafenib—Haemoglobin—Prednisone—Crohn's disease	0.00067	0.00303	CcSEcCtD
Regorafenib—Haemorrhage—Prednisone—Crohn's disease	0.000667	0.00301	CcSEcCtD
Regorafenib—Connective tissue disorder—Prednisone—Crohn's disease	0.000655	0.00296	CcSEcCtD
Regorafenib—Asthenia—Mesalazine—Crohn's disease	0.000642	0.0029	CcSEcCtD
Regorafenib—Vomiting—Azathioprine—Crohn's disease	0.000625	0.00282	CcSEcCtD
Regorafenib—Rash—Azathioprine—Crohn's disease	0.00062	0.0028	CcSEcCtD
Regorafenib—Dermatitis—Azathioprine—Crohn's disease	0.000619	0.0028	CcSEcCtD
Regorafenib—Headache—Azathioprine—Crohn's disease	0.000616	0.00278	CcSEcCtD
Regorafenib—Diarrhoea—Mesalazine—Crohn's disease	0.000613	0.00277	CcSEcCtD
Regorafenib—Angiopathy—Prednisone—Crohn's disease	0.000605	0.00273	CcSEcCtD
Regorafenib—CYP3A4—digestive system—Crohn's disease	0.000599	0.0021	CbGeAlD
Regorafenib—Alopecia—Prednisone—Crohn's disease	0.000589	0.00266	CcSEcCtD
Regorafenib—Nausea—Azathioprine—Crohn's disease	0.000584	0.00264	CcSEcCtD
Regorafenib—Malnutrition—Prednisone—Crohn's disease	0.000581	0.00262	CcSEcCtD
Regorafenib—Vomiting—Mesalazine—Crohn's disease	0.000569	0.00257	CcSEcCtD
Regorafenib—Rash—Mesalazine—Crohn's disease	0.000565	0.00255	CcSEcCtD
Regorafenib—Dermatitis—Mesalazine—Crohn's disease	0.000564	0.00255	CcSEcCtD
Regorafenib—Headache—Mesalazine—Crohn's disease	0.000561	0.00253	CcSEcCtD
Regorafenib—ABCB1—epithelium—Crohn's disease	0.000557	0.00195	CbGeAlD
Regorafenib—Anaemia—Prednisone—Crohn's disease	0.000537	0.00242	CcSEcCtD
Regorafenib—Nausea—Mesalazine—Crohn's disease	0.000532	0.0024	CcSEcCtD
Regorafenib—Hypertension—Prednisone—Crohn's disease	0.000501	0.00226	CcSEcCtD
Regorafenib—ABCG2—lymph node—Crohn's disease	0.000491	0.00172	CbGeAlD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.000491	0.00222	CcSEcCtD
Regorafenib—ABCB1—mammalian vulva—Crohn's disease	0.000483	0.00169	CbGeAlD
Regorafenib—Infection—Prednisone—Crohn's disease	0.000471	0.00212	CcSEcCtD
Regorafenib—Nervous system disorder—Prednisone—Crohn's disease	0.000465	0.0021	CcSEcCtD
Regorafenib—Skin disorder—Prednisone—Crohn's disease	0.00046	0.00208	CcSEcCtD
Regorafenib—ABCB1—lymphoid tissue—Crohn's disease	0.000429	0.0015	CbGeAlD
Regorafenib—ABCB1—digestive system—Crohn's disease	0.000424	0.00149	CbGeAlD
Regorafenib—Decreased appetite—Prednisone—Crohn's disease	0.000412	0.00186	CcSEcCtD
Regorafenib—Fatigue—Prednisone—Crohn's disease	0.000408	0.00184	CcSEcCtD
Regorafenib—Gastrointestinal pain—Prednisone—Crohn's disease	0.000387	0.00175	CcSEcCtD
Regorafenib—Body temperature increased—Prednisone—Crohn's disease	0.000375	0.00169	CcSEcCtD
Regorafenib—Abdominal pain—Prednisone—Crohn's disease	0.000375	0.00169	CcSEcCtD
Regorafenib—Asthenia—Prednisone—Crohn's disease	0.00034	0.00153	CcSEcCtD
Regorafenib—Diarrhoea—Prednisone—Crohn's disease	0.000324	0.00146	CcSEcCtD
Regorafenib—Vomiting—Prednisone—Crohn's disease	0.000301	0.00136	CcSEcCtD
Regorafenib—Rash—Prednisone—Crohn's disease	0.000299	0.00135	CcSEcCtD
Regorafenib—Dermatitis—Prednisone—Crohn's disease	0.000298	0.00135	CcSEcCtD
Regorafenib—Headache—Prednisone—Crohn's disease	0.000297	0.00134	CcSEcCtD
Regorafenib—Nausea—Prednisone—Crohn's disease	0.000281	0.00127	CcSEcCtD
Regorafenib—ABCB1—lymph node—Crohn's disease	0.000242	0.000848	CbGeAlD
Regorafenib—ABL1—Immune System—CRP—Crohn's disease	2.81e-05	6.82e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—TYK2—Crohn's disease	2.81e-05	6.8e-05	CbGpPWpGaD
Regorafenib—ABL1—Axon guidance—IL6—Crohn's disease	2.8e-05	6.79e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—SMAD3—Crohn's disease	2.78e-05	6.74e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—TLR4—Crohn's disease	2.77e-05	6.71e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—CXCL8—Crohn's disease	2.76e-05	6.69e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—SOCS1—Crohn's disease	2.76e-05	6.68e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—SMAD3—Crohn's disease	2.75e-05	6.67e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—SOCS1—Crohn's disease	2.75e-05	6.66e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—RASGRP1—Crohn's disease	2.73e-05	6.62e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL2RA—Crohn's disease	2.73e-05	6.61e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—SMAD3—Crohn's disease	2.72e-05	6.59e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—TLR4—Crohn's disease	2.7e-05	6.54e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—GPX4—Crohn's disease	2.69e-05	6.51e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—JAK2—Crohn's disease	2.68e-05	6.48e-05	CbGpPWpGaD
Regorafenib—MAPK11—Developmental Biology—IL6—Crohn's disease	2.67e-05	6.46e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—UBE2D1—Crohn's disease	2.66e-05	6.45e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—ICAM1—Crohn's disease	2.65e-05	6.43e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—IFNG—Crohn's disease	2.63e-05	6.37e-05	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—STAT3—Crohn's disease	2.62e-05	6.34e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—GCKR—Crohn's disease	2.59e-05	6.29e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—ICAM1—Crohn's disease	2.59e-05	6.27e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—RIPK2—Crohn's disease	2.58e-05	6.26e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—TYK2—Crohn's disease	2.58e-05	6.24e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IL2RA—Crohn's disease	2.57e-05	6.24e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CRP—Crohn's disease	2.57e-05	6.24e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—TYK2—Crohn's disease	2.57e-05	6.22e-05	CbGpPWpGaD
Regorafenib—RAF1—Axon guidance—IL6—Crohn's disease	2.56e-05	6.21e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—FADS1—Crohn's disease	2.56e-05	6.21e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—SMAD3—Crohn's disease	2.55e-05	6.19e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IL2RA—Crohn's disease	2.55e-05	6.18e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—CD4—Crohn's disease	2.54e-05	6.15e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—TYK2—Crohn's disease	2.53e-05	6.13e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL3—Crohn's disease	2.52e-05	6.1e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—SMAD3—Crohn's disease	2.51e-05	6.07e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—FADS1—Crohn's disease	2.5e-05	6.06e-05	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—TNF—Crohn's disease	2.48e-05	6e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—SOCS1—Crohn's disease	2.48e-05	6e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—TLR4—Crohn's disease	2.47e-05	5.98e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—JAK2—Crohn's disease	2.46e-05	5.95e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—JAK2—Crohn's disease	2.45e-05	5.93e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—RASGRP1—Crohn's disease	2.44e-05	5.9e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—JAK2—Crohn's disease	2.41e-05	5.85e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—IFNG—Crohn's disease	2.41e-05	5.84e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—TYK2—Crohn's disease	2.4e-05	5.82e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—GPX4—Crohn's disease	2.4e-05	5.81e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—TYK2—Crohn's disease	2.39e-05	5.8e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—SMAD3—Crohn's disease	2.38e-05	5.77e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—TYK2—Crohn's disease	2.38e-05	5.76e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—SMAD3—Crohn's disease	2.37e-05	5.75e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—IFNG—Crohn's disease	2.37e-05	5.74e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—ICAM1—Crohn's disease	2.37e-05	5.73e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IL2RA—Crohn's disease	2.36e-05	5.73e-05	CbGpPWpGaD
Regorafenib—MAPK11—Innate Immune System—IL6—Crohn's disease	2.36e-05	5.71e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—IL1B—Crohn's disease	2.34e-05	5.68e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GPX4—Crohn's disease	2.34e-05	5.67e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—TYK2—Crohn's disease	2.34e-05	5.66e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—FADS1—Crohn's disease	2.34e-05	5.66e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—CD4—Crohn's disease	2.33e-05	5.64e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PLA2G4F—Crohn's disease	2.32e-05	5.63e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IL2RA—Crohn's disease	2.32e-05	5.62e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—CD4—Crohn's disease	2.32e-05	5.62e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—GCKR—Crohn's disease	2.32e-05	5.61e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—PTGS2—Crohn's disease	2.3e-05	5.58e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—JAK2—Crohn's disease	2.29e-05	5.55e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—CD4—Crohn's disease	2.29e-05	5.54e-05	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	2.28e-05	5.54e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—JAK2—Crohn's disease	2.28e-05	5.54e-05	CbGpPWpGaD
Regorafenib—FGFR1—Developmental Biology—IL6—Crohn's disease	2.28e-05	5.53e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—JAK2—Crohn's disease	2.27e-05	5.5e-05	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—TNF—Crohn's disease	2.27e-05	5.49e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GCKR—Crohn's disease	2.26e-05	5.48e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IFNG—Crohn's disease	2.25e-05	5.45e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IFNG—Crohn's disease	2.24e-05	5.43e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—TYK2—Crohn's disease	2.23e-05	5.41e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—JAK2—Crohn's disease	2.23e-05	5.4e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—STAT3—Crohn's disease	2.22e-05	5.38e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—TYK2—Crohn's disease	2.22e-05	5.37e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—TYK2—Crohn's disease	2.21e-05	5.36e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—SOCS1—Crohn's disease	2.21e-05	5.35e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IL2RA—Crohn's disease	2.2e-05	5.34e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IL2RA—Crohn's disease	2.2e-05	5.32e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GPX4—Crohn's disease	2.19e-05	5.3e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—CD4—Crohn's disease	2.17e-05	5.26e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—CD4—Crohn's disease	2.17e-05	5.25e-05	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—IL6—Crohn's disease	2.16e-05	5.24e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—TYK2—Crohn's disease	2.16e-05	5.23e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—IL1B—Crohn's disease	2.15e-05	5.21e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—CD4—Crohn's disease	2.15e-05	5.21e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—SMAD3—Crohn's disease	2.14e-05	5.18e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—PTGS2—Crohn's disease	2.14e-05	5.17e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—JAK2—Crohn's disease	2.13e-05	5.16e-05	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—IL6—Crohn's disease	2.12e-05	5.15e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—JAK2—Crohn's disease	2.11e-05	5.12e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—IL1B—Crohn's disease	2.11e-05	5.12e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—CD4—Crohn's disease	2.11e-05	5.12e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GCKR—Crohn's disease	2.11e-05	5.12e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TYK2—Crohn's disease	2.11e-05	5.11e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—JAK2—Crohn's disease	2.11e-05	5.11e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—TYK2—Crohn's disease	2.1e-05	5.1e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—TYK2—Crohn's disease	2.1e-05	5.09e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—PTGS2—Crohn's disease	2.1e-05	5.08e-05	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—IL6—Crohn's disease	2.08e-05	5.04e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—JAK2—Crohn's disease	2.06e-05	4.99e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IFNG—Crohn's disease	2.02e-05	4.89e-05	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—IL6—Crohn's disease	2.02e-05	4.88e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—JAK2—Crohn's disease	2.01e-05	4.88e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—IL6—Crohn's disease	2.01e-05	4.87e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—JAK2—Crohn's disease	2.01e-05	4.86e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—JAK2—Crohn's disease	2.01e-05	4.86e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IL1B—Crohn's disease	2.01e-05	4.86e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—CD4—Crohn's disease	2e-05	4.86e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IL1B—Crohn's disease	2e-05	4.85e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—CD4—Crohn's disease	2e-05	4.84e-05	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—IL6—Crohn's disease	2e-05	4.84e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—TYK2—Crohn's disease	1.99e-05	4.83e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—PTGS2—Crohn's disease	1.99e-05	4.82e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—PTGS2—Crohn's disease	1.98e-05	4.81e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL2RA—Crohn's disease	1.98e-05	4.8e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—MTMR3—Crohn's disease	1.98e-05	4.79e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IFNG—Crohn's disease	1.97e-05	4.77e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—STAT3—Crohn's disease	1.96e-05	4.76e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CD4—Crohn's disease	1.95e-05	4.73e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—CXCL8—Crohn's disease	1.94e-05	4.71e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—TYK2—Crohn's disease	1.92e-05	4.66e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—SMAD3—Crohn's disease	1.91e-05	4.62e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CD4—Crohn's disease	1.9e-05	4.61e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—JAK2—Crohn's disease	1.9e-05	4.6e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	1.85e-05	4.49e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—CXCL8—Crohn's disease	1.84e-05	4.45e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—JAK2—Crohn's disease	1.83e-05	4.44e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—CXCL8—Crohn's disease	1.83e-05	4.44e-05	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—IL6—Crohn's disease	1.83e-05	4.43e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TYK2—Crohn's disease	1.81e-05	4.39e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—IL6—Crohn's disease	1.81e-05	4.39e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—STAT3—Crohn's disease	1.8e-05	4.37e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL1B—Crohn's disease	1.8e-05	4.37e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—CD4—Crohn's disease	1.8e-05	4.36e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IFNG—Crohn's disease	1.8e-05	4.36e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TYK2—Crohn's disease	1.8e-05	4.35e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—STAT3—Crohn's disease	1.8e-05	4.35e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—PTGS2—Crohn's disease	1.79e-05	4.33e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—TYK2—Crohn's disease	1.78e-05	4.3e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—STAT3—Crohn's disease	1.77e-05	4.29e-05	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—IL6—Crohn's disease	1.77e-05	4.28e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL2RA—Crohn's disease	1.76e-05	4.28e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL1B—Crohn's disease	1.76e-05	4.25e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CD4—Crohn's disease	1.74e-05	4.21e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—JAK2—Crohn's disease	1.73e-05	4.19e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—JAK2—Crohn's disease	1.71e-05	4.15e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—JAK2—Crohn's disease	1.69e-05	4.1e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—STAT3—Crohn's disease	1.68e-05	4.07e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—STAT3—Crohn's disease	1.68e-05	4.06e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TYK2—Crohn's disease	1.67e-05	4.04e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—STAT3—Crohn's disease	1.67e-05	4.03e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	1.66e-05	4.01e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TYK2—Crohn's disease	1.64e-05	3.96e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—STAT3—Crohn's disease	1.64e-05	3.96e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	1.62e-05	3.93e-05	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—IL6—Crohn's disease	1.61e-05	3.91e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL1B—Crohn's disease	1.61e-05	3.89e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—CD4—Crohn's disease	1.61e-05	3.89e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—PTGS2—Crohn's disease	1.59e-05	3.86e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—JAK2—Crohn's disease	1.59e-05	3.85e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CXCL8—Crohn's disease	1.58e-05	3.83e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—ALB—Crohn's disease	1.57e-05	3.8e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—ALB—Crohn's disease	1.57e-05	3.8e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CXCL8—Crohn's disease	1.56e-05	3.79e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—STAT3—Crohn's disease	1.56e-05	3.79e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—JAK2—Crohn's disease	1.56e-05	3.78e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TYK2—Crohn's disease	1.55e-05	3.76e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—STAT3—Crohn's disease	1.55e-05	3.76e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—IL6—Crohn's disease	1.55e-05	3.76e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TYK2—Crohn's disease	1.55e-05	3.75e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—STAT3—Crohn's disease	1.55e-05	3.75e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—FADS1—Crohn's disease	1.54e-05	3.73e-05	CbGpPWpGaD
Regorafenib—ABCB1—Transmembrane transport of small molecules—ALB—Crohn's disease	1.54e-05	3.72e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—STAT3—Crohn's disease	1.51e-05	3.66e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	1.51e-05	3.66e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—JAK2—Crohn's disease	1.48e-05	3.59e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—STAT3—Crohn's disease	1.48e-05	3.58e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—JAK2—Crohn's disease	1.48e-05	3.58e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—STAT3—Crohn's disease	1.47e-05	3.57e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CXCL8—Crohn's disease	1.45e-05	3.51e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	1.45e-05	3.51e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GPX4—Crohn's disease	1.44e-05	3.49e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CXCL8—Crohn's disease	1.42e-05	3.45e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TYK2—Crohn's disease	1.39e-05	3.38e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—STAT3—Crohn's disease	1.39e-05	3.38e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GCKR—Crohn's disease	1.39e-05	3.37e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—IL6—Crohn's disease	1.37e-05	3.32e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—PTGS2—Crohn's disease	1.37e-05	3.32e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—PTGS2—Crohn's disease	1.37e-05	3.32e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CXCL8—Crohn's disease	1.35e-05	3.27e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CXCL8—Crohn's disease	1.35e-05	3.27e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—STAT3—Crohn's disease	1.35e-05	3.26e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—ALB—Crohn's disease	1.33e-05	3.22e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—JAK2—Crohn's disease	1.33e-05	3.22e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	1.32e-05	3.2e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—STAT3—Crohn's disease	1.27e-05	3.08e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—IL6—Crohn's disease	1.26e-05	3.05e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—STAT3—Crohn's disease	1.26e-05	3.05e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—IL6—Crohn's disease	1.26e-05	3.04e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TYK2—Crohn's disease	1.24e-05	3.01e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—STAT3—Crohn's disease	1.24e-05	3.01e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—IL6—Crohn's disease	1.24e-05	3e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CXCL8—Crohn's disease	1.21e-05	2.94e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—JAK2—Crohn's disease	1.19e-05	2.87e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IL6—Crohn's disease	1.17e-05	2.85e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IL6—Crohn's disease	1.17e-05	2.84e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—STAT3—Crohn's disease	1.17e-05	2.83e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PTGS2—Crohn's disease	1.16e-05	2.82e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—IL6—Crohn's disease	1.16e-05	2.82e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—STAT3—Crohn's disease	1.15e-05	2.77e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—IL6—Crohn's disease	1.14e-05	2.77e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—IL6—Crohn's disease	1.09e-05	2.65e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—STAT3—Crohn's disease	1.09e-05	2.63e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—IL6—Crohn's disease	1.08e-05	2.63e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—STAT3—Crohn's disease	1.08e-05	2.63e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CXCL8—Crohn's disease	1.08e-05	2.62e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—IL6—Crohn's disease	1.08e-05	2.62e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL6—Crohn's disease	1.06e-05	2.56e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—IL6—Crohn's disease	1.03e-05	2.5e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—IL6—Crohn's disease	1.03e-05	2.49e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL6—Crohn's disease	1.03e-05	2.49e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—STAT3—Crohn's disease	9.77e-06	2.37e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—ALB—Crohn's disease	9.75e-06	2.36e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—IL6—Crohn's disease	9.74e-06	2.36e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL6—Crohn's disease	9.4e-06	2.28e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IL6—Crohn's disease	8.87e-06	2.15e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IL6—Crohn's disease	8.79e-06	2.13e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—STAT3—Crohn's disease	8.7e-06	2.11e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—IL6—Crohn's disease	8.68e-06	2.1e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PTGS2—Crohn's disease	8.53e-06	2.07e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—ALB—Crohn's disease	8.26e-06	2e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IL6—Crohn's disease	8.15e-06	1.97e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IL6—Crohn's disease	8e-06	1.94e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IL6—Crohn's disease	7.59e-06	1.84e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IL6—Crohn's disease	7.57e-06	1.83e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ALB—Crohn's disease	7.37e-06	1.79e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PTGS2—Crohn's disease	7.23e-06	1.75e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ALB—Crohn's disease	7.19e-06	1.74e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL6—Crohn's disease	6.82e-06	1.65e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ALB—Crohn's disease	6.72e-06	1.63e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PTGS2—Crohn's disease	6.45e-06	1.56e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PTGS2—Crohn's disease	6.29e-06	1.53e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL6—Crohn's disease	6.08e-06	1.47e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PTGS2—Crohn's disease	5.88e-06	1.42e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ALB—Crohn's disease	4.43e-06	1.07e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PTGS2—Crohn's disease	3.88e-06	9.4e-06	CbGpPWpGaD
